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Abstract 
Photodynamic therapy (PDT) is a light-based treatment modality in which wavelength specific 
activation of a photosensitizer (PS) generates cytotoxic response in the irradiated region. 
PDT response is critically dependent on several parameters including light dose, PS dose, 
uptake time, fluence rate, and the mode of light delivery. While the systematic optimization of 
these treatment parameters can be complex, it also provides multiple avenues for en-
hancement of PDT efficacy under diverse treatment conditions, provided that a rational 
framework is established to quantify the impact of parameter selection upon treatment re-
sponse. Here we present a theranostic technique, combining the inherent ability of the PS to 
serve simultaneously as a therapeutic and imaging agent, with the use of image-based 
treatment assessment in three dimensional (3D) in vitro tumor models, to comprise a platform 
to evaluate the impact of PDT parameters on treatment outcomes. We use this approach to 
visualize and quantify the uptake, localization, and photobleaching of the PS benzoporphyrin 
derivative monoacid ring-A (BPD) in a range of treatment conditions with varying uptake 
times as well as continuous and fractionated light delivery regimens in 3D cultures of AsPC-1 
and PANC-1 cells. Informed by photobleaching patterns and correlation with cytotoxic re-
sponse, asymmetric fractionated light delivery at 4 hours BPD uptake was found to be the 
most effective regimen assessed. Quantification of the spatial profile of cell killing within 
multicellular nodules revealed that these conditions also achieve the highest depth of cyto-
toxicity along the radial axis of 3D nodules. The framework introduced here provides a means 
for systematic assessment of PDT treatment parameters in biologically relevant 3D tumor 
models with potential for broader application to other systems. 
Key words: Photodynamic therapy, PDT, photosensitizer imaging, fractionation, verteporfin, BPD, 
in vitro 3D tumor model. 
Introduction 
Photodynamic therapy (PDT) is an emerging 
anticancer treatment [1-5] that uses a light-activated 
chemical, or photosensitizer (PS) which localizes 
somewhat preferentially in neoplastic tissue and in-
duces a cytotoxic response upon activation by the 
appropriate wavelength of light [6]. The cytotoxic 
response generated by PDT can be enhanced by ad-
justing a panoply of parameters which include light 
dose, photosensitizer dose, uptake time, irradiance, 
and light delivery modulation. This large set of ther-
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apeutic parameters simultaneously elevates the com-
plexity of the treatment and provides multiple ave-
nues for customization and optimization. Important-
ly, most PDT agents are intrinsically theranostic as 
they are useful both for therapeutic and for diagnostic 
purposes. This is because the photosensitizing species 
used for PDT, in addition to generating cytotoxicity, 
also almost universally have a finite quantum yield 
for fluorescence emission, providing a powerful in-
trinsic capability for monitoring of uptake, localiza-
tion, and photobleaching, which can in turn be uti-
lized to inform these critical variables in treatment 
design. In addition, the fluorescence can be used for 
diagnostic applications such as image-guided resec-
tion [6, 7]. Here, we present a methodology which 
combines the unique ability of the PS to serve simul-
taneously as an imaging agent and a light-activated 
therapeutic; with 3D tumor models that restore 
physiologically-relevant tumor architecture and are 
conducive to interrogation by optical imaging. 
Building on the previous development of 
high-content image processing for therapeutic as-
sessment in 3D cancer models [8, 9], we integrate a 
new set of analyses for in situ quantification of pho-
tosensitizer uptake, localization, and photobleaching 
to comprise a new theranostic approach for spa-
tio-temporal correlation of PDT parameters and 
treatment effects across populations of individual in 
vitro 3D tumor micronodules that resemble multifocal 
nodular studding in vivo. We further demonstrate the 
ability of this integrative platform to inform the op-
timization PDT parameters.  
Optimization of dosimetry in PDT is a complex 
process that is usually system specific and depends on 
many parameters that are closely interrelated. Such 
parameters include light dose, light fluence rate, con-
centration of photosensitizer administered, and pho-
tosensitizer uptake time [10, 11]. To address the dif-
ficulties that dosimetry presents, many prior studies 
have focused on quantification of photosensitizer 
photobleaching as an indicator of treatment efficacy 
[12-14]. Others studies have involved imaging pho-
tosensitizer localization and uptake [15, 16] while 
fewer have attempted to monitor singlet oxygen gen-
eration and/or triplet oxygen depletion to determine 
optimal irradiation times [17, 18]. Singlet oxygen de-
tection is arguably the most direct way of predicting 
treatment efficacy in oxygen-dependent PDT and thus 
optimizing treatment regimens, but it is very difficult 
to accurately measure in practice. Photobleaching, 
while less direct, generally correlates well with cyto-
toxic response, is affected by nearly all of the adjusta-
ble parameters (e.g., light dose, irradiance, photosen-
sitizer dose, etc.), and is far easier to quantify and, in 
some cases, visualize.  
Another adjustable parameter, the determination 
of which can be aided by our technique, is modulation 
of light delivery. An extensively studied [18-20] ad-
justment is the fractionation of delivered light, which 
involves irradiating with interspersed rest periods in 
which no light is administered until a total fluence is 
achieved (e.g., a 33s on/33s off/33s on schedule to 
achieve a 10 J/cm2 light dose at 150 mW/cm2). 
Though the benefit from fractionated irradiation ob-
served, if any, is highly dependent on the system 
studied (e.g., photosensitizer used, oxygenation con-
ditions, etc.) [21-23], it has been suggested that the 
effect is mainly due to reoxygenation of hypoxic tu-
mor regions [24, 25]. Increased PPIX production dur-
ing the dark intervals of fractionated ALA-PDT has 
also been suggested [26]. Consequently, any en-
hancement in cytotoxic response would be expected 
to correlate with photobleaching patterns. Therefore, 
fractionation regimens can be chosen based on in-
formed analyses from our imaging-based technique. 
To demonstrate this utility, we pursued asymmetric 
in addition to symmetric fractionation regimens on 
the seconds scale as we hypothesized shorter irradia-
tion intervals would result in less photobleaching 
while longer dark intervals would allow greater re-
oxygenation, a methodology somewhat similar to 
radiotherapy treatments. Asymmetric fractionation 
regimens would consist of 33s on/66s off, 33s on/99s 
off, et cetera, irradiation schemes. 
In this study, we explore each of the PDT pa-
rameters mentioned above in a three-dimensional 
cancer model. As a result of the current interest in 
PDT as a potential treatment for pancreatic ductal 
adenocarcinoma [27], we have elected to use the pan-
creatic cancer cell lines AsPC-1 and PANC-1 for the 
development and demonstration of our imag-
ing-based method. Three-dimensional in vitro cell 
culture models have, in recent years, been developed 
into more physiologically relevant and more reliable 
reporters of treatment response than conventional 
monolayer cultures [9]. Here we employ a 3D culture 
overlay geometry adapted from a system previously 
characterized using ovarian cancer lines that is con-
ducive to high-content imaging [8, 9, 28]. In addition 
to the new imaging approaches introduced here, we 
also utilize previously described [8, 9, 27, 29] imag-
ing-based techniques to quantify cytotoxic response in 
large fields consisting of thousands of nodules. The 
capabilities of the imaging-based method to be pre-
sented will thus be leveraged to visualize and quan-
tify the results of PDT parameter adjustment by mon-
itoring uptake, localization, and photobleaching pat-
terns. 




Methods and Materials 
Cell Lines and Reagents 
AsPC-1 and PANC-1 cell lines were obtained 
from American Type Culture Collection (ATCC, 
Rockville, MD) and grown according to ATCC de-
scriptions. Cell media and fetal bovine serum were 
obtained from Mediatech (Herndon, VA) and Invi-
trogen (Carlsbad, CA), respectively. To all cell media 
was added 50 IU/mL penicillin and 50 mg/mL 
streptomycin (Mediatech). PDT treatments were 
conducted using the photosensitizer benzoporphyrin 
derivative monoacid ring-A (BPD, common name 
Verteporfin, VWR, Radnor, PA). Quoted concentra-
tions of BPD were confirmed using its UV-VIS ab-
sorbance spectrum and previously characterized 
photophysical properties [30].  
Growth of 3D Tumor Nodules on Basement 
Membrane 
Cells were grown in overlay on a bed of Growth 
Factor Reduced (GFR) Matrigel™ (BD Biosciences, 
Bedford, MA) as a basement membrane to mimic 
stromal interactions in pancreatic cancer, as previ-
ously described [8, 27, 31]. In this work, 250 μL of 
Matrigel was deposited into each well of a 24-well 
plate so that beds several hundred microns in thick-
ness completely covered the well bottoms. As cells 
were plated in overlay and not embedded in the ma-
trix, any variations in the bed thickness will not affect 
growth and/or treatment outcomes. Cells were 
grown for 10 to 12 days prior to initiation of treatment 
and/or imaging of BPD uptake. Media changes with 
2% GFR Matrigel-supplemented media were per-
formed once every third day during the growth pro-
cess. To illustrate the three-dimensional structure of 
the nodules, comprehensive Z-stack images of 
cleaved Calcein and Propidium Iodide fluorescence, 
which label viable and dead cells, respectively, were 
taken on the Olympus FV-1000 confocal at 40X for 
treated and untreated day 12 AsPC-1 nodules. Images 
acquired at representative Z-positions as well as 3D 
renderings of each Z-stack are presented in Addition-
al File 1: Supplemental Figure 1. At the time of imag-
ing and PDT treatment, the 3D cultures for both cell 
lines had adopted a highly reproducible bimodal 
Gaussian distribution of nodule sizes (see Additional 
File 1: Supplemental Figure 2). 
Imaging of Verteporfin (BPD) Uptake and 
Localization 
 On the day of imaging, cells were incubated 
with 1 μM BPD in cell media for various time intervals 
quoted in the text. BPD media was then replaced with 
BPD-free media. To quantify verteporfin uptake and 
localization within tumor nodules, an imaging-based 
method was developed for the three-dimensional 
model to quantify uptake and localization of BPD 
using fluorescence imaging. Images were obtained 
using an Olympus FV-1000 confocal microscope. The 
photosensitizer was excited with the 488 nm line from 
an Argon ion laser. Optimal dichroic mirror, filter, 
and detector settings for the fluorescence channel 
were established by imaging BPD, the spectrum of 
which was verified in hyperspectral scans. For all BPD 
fluorescence images, an objective magnification of 4X 
(NA = 0.16) was used to collect single-images that 
were digitally zoomed by a factor of 1.4. Each imaged 
area was 2.3 mm x 2.3 mm in size and consisted of 
approximately one hundred nodules. Individual 
treatment groups were performed in triplicate, yield-
ing statistics across hundreds of nodules. While a 
confocal microscope was used for image acquisition, 
the confocality of the instrument was not necessary 
for our technique: the confocal pinhole diameter was 
opened to 600 μm to collect the maximal amount of 
fluorescence signal. With this aperture size, the 
in-plane resolution and optical section thickness were 
estimated to be 1.5 μm and 310 μm, respectively. In-
dividual image fields were saved for offline pro-
cessing using routines that we developed in 
MATLAB.  
The analysis routine first calculates mean pixel 
intensities of each individual fluorescence image. The 
average fluorescence intensities from the no treatment 
groups are then assumed to be background and sub-
tracted from the mean fluorescence intensities of 
groups which received photosensitizer. The back-
ground subtracted fluorescence intensities are then 
used as a metric for reporting the relative mean con-
centration of photosensitizer in the nodules. In addi-
tion, individual matrix elements of post-treatment 
images are subtracted from each pre-treatment image 
element to generate photobleaching maps.  
Quantification of Verteporfin (BPD) Photo-
bleaching 
 Photobleaching effects were visualized by im-
aging each well of the plates pre- and post- PDT 
treatment. Identical imaged areas were acquired di-
rectly before and after PDT treatment and during 
evaluation of cytotoxic response. Using the afore-
mentioned MATLAB routines, mean fluorescence 
intensity of the pre- and post- treatment images was 
calculated and the mean residual BPD in each group 
reported as the ratio of the residual BPD of each 
treatment group to that of the BPD only control. 
Photobleaching maps were also generated by sub-




tracting each element of the post-treatment image 
matrix from each element of the pre-treatment’s im-
age and visualized with the “hot” color map in 
MATLAB. Pixel intensity line scans of individual 
nodules from raw fluorescence images were per-
formed using the public domain image analysis soft-
ware ImageJ [32]. 
PDT Treatments 
Cell cultures were incubated with medium con-
taining 1 μM BPD for time intervals of 1.5, 4, and 24 
hours. Prior to irradiation, the medium was replaced 
with BPD-free medium. Cells were irradiated at spec-
ified doses using a 690 nm laser diode source (Model 
7401; Intense, North Brunswick, NJ) at a fluence rate 
of 150 mW/cm2 as measured via a VEGA laser power 
energy meter (Ophir Laser Measurement Group, LLC) 
and then allowed to incubate for 24 hours prior to 
evaluation of treatment response. Laser irradiation 
was delivered through the bottom of each well on a 
clear plastic tray via a vertically mounted Thorlabs 
FT600EMT multimode fiber (Thorlabs, Newton, NJ), 
which was collimated to overfill the dish area for 
nearly uniform light delivery.  
A robust system that integrates an electronic TTL 
logic shutter and computer code was used to provide 
highly reproducible light doses. The irradiation times 
corresponding to specified light doses were calculated 
to the nearest hundredth of a second using a custom 
routine written in C and compiled in Igor Pro 
(Wavemetrics, Lake Oswego, OR). The program also 
runs a USB-6210 counter/timer board (National In-
struments), which creates +5V TTL pulse trains to 
operate an Ocean Optics INLINE-TTL-S fiber-coupled 
shutter (Ocean Optics, Dunedin, FL) to deliver light 
consistently for the calculated irradiation interval. For 
continuous irradiation treatments, the pulse train 
from the counter/timer board consisted of one pulse 
in HIGH logic (+5V, open shutter) for the duration of 
the treatment. For fractionated light delivery, irradia-
tion periods correspond to the time in which the pulse 
train is in HIGH logic, while LOW logic (-5V, closed 
shutter) corresponds to dark intervals. Fractionation 
regimens were determined by splitting the counter-
part continuous light dose in half (i.e., only one rest 
period), beginning with symmetric fractionation (e.g., 
33s on/33s off) and then increasing the asymmetry of 
the light/dark interval (e.g., 33s on/66s off, etc.). A 
fluence of 10 J/cm2 is therefore accomplished by irra-
diating in a 33s on/33s off/33s on fractionation 
schedule.  
Cell Viability Measurements 
Viability of treated cultures was assessed using a 
previously described [8, 9] imaging-based technique 
to quantify cells positively stained with Calcein AM 
(Invitrogen) as a fluorescent label for viable cells and 
Propidium Iodide (Sigma Aldrich) as a marker for 
dead cells. All wells were incubated with Calcein AM 
and Propidium Iodide reagents for 40 minutes prior to 
imaging on an Olympus FV-1000 confocal microscope 
using a 0.16NA 4X objective to obtain single-image 
fields 2.3 mm x 2.3 mm in size consisting of many 
nodules. The 488 nm line from an Argon ion laser 
with paired with a FITC filter set and a 559 nm diode 
source paired with a TRITC filter set was used to de-
tect cleaved Calcein and intercalated Propidium, la-
beling viable and dead cells respectively. Saved im-
ages were batch-processed in MATLAB using a rou-
tine to segment the fluorescence images, determine 
mean pixel intensities for the Calcein (live) and Pro-
pidium Iodide (dead) channels separately, and sub-
sequently calculate viability from the mean intensities 
using the formula live/(live+dead) as previously de-
scribed [8] and also using a complete killing control 
(fixed and permeablized cultures) to standardize the 
dynamic range of fluorescence intensity from the two 
channels [29]. Fractional viability was reported as the 
ratio of the viability of a given treatment group to that 
of the no treatment control group for identical plating 
conditions and growth period. Validation of this im-
aging-based approach to quantifying treatment re-
sponse in the 3D model against common colorimetric 
assays is not straightforward as assay reagents (e.g., 
MTT) bind to the Matrigel substrate. However, the 
method has been used previously in monolayer cell 
cultures [9] and provided comparable viabilities to 
that obtained via the MTT assay (see Additional File 1: 
Supplemental Figure 3). 
Results  
Overview of PDT Treatment Parameters and 
the Imaging-Based Method 
Figure 1 gives an overview of the parameters 
involved in a given PDT treatment as well as the ca-
pabilities of our imaging-based technique. PS fluo-
rescence images are displayed based on a 12-bit col-
ormap to easily identify areas of high pixel intensity. 
As expected, the No Treatment group contains no 
photosensitizer fluorescence (each image is nearly 
black) while the viability assessment image contains 
bright green nodules, signifying their health. Photo-
bleaching of the photosensitizer can be qualitatively 
observed as a decrease in mean pixel intensity when 
comparing the pre- and post-treatment PS colormaps 
for a PDT treatment in which a fluence of 10 J/cm2 
was delivered continuously.  





Figure 1: Imaging-based Quantification of Photosensitizer Uptake, Localization and Photobleaching. Overview of PDT 
treatment parameters and the capabilities of the imaging-based approach. The “Change in PS” column denotes pixel-by-pixel subtraction 
of post-treatment from pre-treatment photosensitizer fluorescence images. The most intense pixels in these images correspond to the 
pixels that were the most photobleached by PDT. Green and red pixels in fluorescence images in the “Imaging Based Viability Assessment” 
column denote live and dead characteristics of the nodules, respectively. All data presented here was collected from day 12 AsPC-1 
cultures that were allowed to uptake photosensitizer for 4 hours. All scale bars are 350 μm. 




The “Change in PS” colormap is the result of 
subtracting the post-treatment image element-wise 
from the pre-treatment image and plotted on the same 
12-bit colormap. Areas of high photobleaching are 
thus visualized here as areas of high pixel intensity. 
Though the mathematical basis for this image trans-
formation does not scale pixels to give the percent 
photobleaching for each pixel, it is a useful reporter of 
the localization of photobleaching in the nodules, and 
will heretofore be referred to as the “photobleaching 
map.” Finally, dead regions of cells in the viability 
assessment can be qualitatively correlated to the high 
pixel intensities of the photobleaching map. 
These raw fluorescence images and the calcu-
lated photobleaching map thus provide rich and 
thorough information about PDT parameters. Firstly, 
PS fluorescence images collected pre-treatment pro-
vide a means to quantify not only mean, but nod-
ule-by-nodule photosensitizer uptake and localiza-
tion. Pixel intensity line scans (shown as white arrows 
in each enlarged nodule images) of single nodules 
reveal the photosensitizer’s localization within the 
acini. It can be seen in Figure 1 that photosensitizer is 
localized primarily on the outer edges of the nodule 
(blue plot, left). From this information, uptake curves 
are obtained by imaging selected groups of nodules 
that are administered photosensitizer at different up-
take times and then taking the mean pixel intensity of 
each image (see Figure 2). Similar information is ob-
tained regarding the degree and localization of nod-
ule-by-nodule photobleaching. The plot profile of the 
same nodule in the photobleaching map shows that 
not only is photosensitizer primarily located on the 
periphery of the nodule, but that photobleaching is 
highest in the same region (red plot, middle). In the 
live and dead fluorescence images under the “Imag-
ing-based Viability Assessment” panel in Figure 1, it 
can be seen that the same nodule has nearly no viable 
cells in the analogous region where photobleaching 
was maximal. Consequently, the most viable cells 
survive in the core of the nodule where photobleach-
ing was minimal. 
 
Figure 2: BPD Uptake Curves for 
PANC-1 and AsPC-1 3D Cultures. 
Method by which photosensitizer uptake 
curves are obtained in the 3D model, 
beginning with (A) BPD fluorescence 
images of day 10 PANC-1 cultures taken 
5 minutes after media change to 
BPD-free media (images from AsPC-1 
cultures not shown for the sake of clar-
ity). Quantified uptake curves were 
generated by taking the mean pixel in-
tensities of each image and are presented 
for (B) day 12 AsPC-1 and (C) day 10 
PANC-1 nodules. Ratiometric increases 
in (B) and (C) are reported as the ratio of 
the mean pixel intensities of images 
collected at 24 hours of uptake to those 
collected at 1 hour of uptake. All scale 
bars are 350 μm. 
 
  




Perhaps the most robust capability of our imag-
ing-based technique is the correlation of photo-
bleaching to treatment response, as shown at the bot-
tom of Figure 1. In particular, the mean residual 
photosensitizer (blue bars, bottom graph) can be cor-
related to mean cytotoxic response (red bars) obtained 
from the viability assessment. Using this data, it can 
be seen that increasing the light dose results in en-
hanced cytotoxic response as well as increased mean 
photobleaching. Nodule-by-nodule photobleaching 
patterns can again be correlated to live and dead pat-
terns seen during treatment evaluation. This is seen in 
the bottom right plot profile in Figure 1: the pixel in-
tensity profile for the photobleaching map (black line) 
aligns with the live (green line) and dead (red line) 
profiles for a selected 10 J/cm2 continuous irradiation 
PDT treatment. It should be noted that the observed 
alignment at this point is only quasi-quantitative. The 
correlation cannot be perfect as the nodule surface 
area changes during the 24 hour period in between 
treatment and evaluation due to migration of dead 
cells from the nodule and continuing growth of viable 
cells within the acinus core. The extent of this fluctua-
tion is visible in the bottom right plot profile pre-
sented in Figure 1.  
Verteporfin Localization and Uptake in 3D 
AsPC-1 and PANC-1 Cultures  
Figure 2 illustrates how photosensitizer uptake 
curves are obtained with our imaging methodology 
and how localization can be visualized. Acquired 
images from the transmitted light and BPD fluores-
cence channels from day 10 PANC-1 nodules (Figure 
2A) show that no BPD is present in the No Treatment 
control, and that both the BPD concentration and lo-
calization within the nodules changes with uptake 
time. At early uptake durations (1-3 hours), the pho-
tosensitizer fluorescence is weak and localized pri-
marily in the outer crust of the nodules. As uptake 
time increases, the inner-most cells in the acini gather 
more BPD from the cell medium while outer-most 
cells reach a relatively constant concentration soon 
after exposure to the drug. That is, the uptake time for 
the outermost cells is likely more rapid than for those 
in the nodule core, whose nutrient transport rates are 
limited by the presence of multiple cellular layers 
within the nodule. A similar trend is observed in the 
AsPC-1 cell line (not shown). Unlike uptake data 
taken with these cell lines grown in monolayer, where 
uptake is steep up to 4 hours, but then decreases 
sharply [27], the BPD concentration in 
three-dimensional nodules continues to intensify out 
to 24 hours of drug uptake. 
Using our custom MATLAB routines, the mean 
fluorescence intensity in the raw images was deter-
mined, giving a relative estimation of the amount of 
photosensitizer in the nodules at each time point. The 
resulting uptake curves for day 12 AsPC-1 and day 10 
PANC-1 cultures are presented in Figures 2B and 2C, 
respectively. The fluorescence intensities of PANC-1 
and AsPC-1 cultures are not comparable as different 
dynamic ranges were used during imaging. However, 
the increase in relative fluorescence intensity between 
BPD uptake for 1 hour and 24 hours for the AsPC-1 
and PANC-1 cultures was 4.4 and 5.7 fold, respec-
tively. This shows that PANC-1 nodules acquire 
photosensitizer faster than AsPC-1 acini, another re-
sult that is different from patterns seen in monolayer 
data [27].  
Optimization of Uptake-dependent PDT 
Treatment Parameters 
To determine the effect of uptake and localiza-
tion on treatment response, we conducted continuous 
irradiation PDT treatments at 1.5 hour, 4 hour, and 24 
hour uptake times for both AsPC-1 and PANC-1 cell 
lines. The 4 hour time point was chosen as the uptake 
curves in Figure 2 plateau around 4-5 hours while 1.5 
hours was chosen as it has been previously studied in 
3D cultures [27]. Though 24 hour BPD uptake is not 
practical in in vivo models because of BPD’s pharma-
cokinetics [33], it was nevertheless informative to 
examine this upper limit in this mechanistic study. 
Figure 3 shows the results of these experiments. It is 
readily seen that cytotoxic response is dependent on 
uptake time for both cell lines. For AsPC-1 cells, at 
lower light doses (i.e., 5 J/cm2), there is a marked en-
hancement in killing with increasing uptake. Howev-
er, killing is either worse or unchanged at higher light 
doses. PANC-1 cultures show similar behavior, 
though killing increases going from 1.5 hours to 4 
hours with all light doses. 
Optimization of Fractionated Light Delivery 
from Photobleaching Patterns 
Figure 4 shows the change in treatment response 
of 10 J/cm2 delivered continuously and fractionated 
(symmetric and asymmetric regimens) with uptake 
time in day 12 AsPC-1 cultures. Fractionation sched-
ules are reported as seconds on/seconds off (33/0 
denotes continuous irradiation, no rest period). Re-
ported p-values are subscript symbolized as the 
comparison between groups with two different dark 
intervals for clarity. At only 1.5 hours of verteporfin 
uptake, there is no discernable difference between any 
fractionation schedule and continuous irradiation. 
However, a significant benefit from symmetric frac-
tionation is observed at 4 hours. A two-tailed student 




t-test reveals that comparing no dark interval (0s off, 
continuous irradiation) to symmetric (33s off) and 
asymmetric fractionation (99s off) at 1.5 hours uptake 
results in p-values of p0-33=0.572 and p0-99=0.531, re-
spectively. The result of this same comparison at 4 
hours uptake is p0-33=0.004 and p0-99<0.001. At 4 hours 
uptake, symmetric fractionation (33s on/33s off) does 
provide a modest enhancement, and increasingly 
asymmetric fractionation (33s on/99s off) provides 
even more. To determine why this occurs, we meas-
ured the mean photobleaching at 4 hours uptake in 
day 12 AsPC-1 cultures for 10 J/cm2 33s/0s and 
33s/99s, and then correlated that to mean cytotoxic 
response. Figure 4B shows the result of this analysis 
and that the enhancement between continuous irra-
diation and asymmetric fractionation is present and 
significant (pV=0.016), but that there is an insignificant 
difference between the mean residual BPD in the 
wells (pBPD=0.115). From this data, it is clear that, in 
comparison to the absence of a dark interval, a statis-
tically significant and greater cytotoxic response is 
obtained by fractionating delivered light. However, 
the reason for this enhancement cannot be readily 
elucidated by using mean field methods to quantify 
residual BPD or photobleaching. 
 
 
Figure 3: Uptake Dependent Treatment Response for 
PANC-1 and AsPC-1 Cultures (Continuous Irradiation). 
Variable treatment response for 5, 10, and 20 J/cm2 irradiance 
delivered continuously with increasing BPD uptake time for (A) 









Figure 4: Uptake Dependent Treatment Response for 
AsPC-1 Cultures (Fractionated Irradiation). (A) Variable 
treatment response with uptake time for a constant 10J/cm2 light 
dose delivered continuously (33s on/0s off) and with increasing 
rest-period asymmetry (33s on/33s off, 33s on/66s off, etc.) for day 
12 AsPC-1 nodules. Fractionation schedules are reported as 
seconds on/seconds off. Reported p-values are subscript symbol-
ized as the comparison between groups with two different dark 
intervals for clarity. (B) Correlation of mean residual BPD to mean 
viability in day 12 AsPC-1 nodules with 4 hours of BPD uptake. 
Mean residual BPD was normalized to the BPD-only control. 
 




To determine why fractionation produces a 
larger cytotoxic response than continuous irradiation, 
we further leverage our imaging based approach to 
correlate spatial photobleaching patterns with uptake 
and light delivery parameters. Figure 5 summarizes 
the data extracted from treatments at 1.5 hours and 4 
hours of uptake for day 12 AsPC-1 nodules. Photo-
bleaching maps were generated for the continuous 
irradiation and 33s on/99s off regimens for both 1.5 
hours and 4 hours of BPD uptake. Pixel intensity line 
scans of the photobleaching maps were taken from 
nodules that were determined to be of similar diame-
ter along their minor axis (~200 μm) and aspect ratio. 
Each line profile presents two peaks on the periphery 
of the nodules while the acini cores contain a large dip 
in the pixel intensity. There is little difference in the 
distribution of photobleaching comparing only con-
tinuous and fractionated light delivery. However, the 
thickness of the photobleaching “depth” is dissimilar 
comparing 1.5 hours to 4 hours of BPD uptake. The 
width of the photobleaching peaks are ~10-40 μm for 
1.5 hours uptake while peaks on similarly sized nod-
ules are ~80-100 μm at 4 hours. Referring back to 
Figure 1, the depth of photobleaching roughly corre-
sponds to regions of dead cells from the evaluation of 
cytotoxic response. This suggests that broader photo-
bleaching peaks correspond to deeper penetration of 
cytotoxicity in the acini, as observed from the data in 
Figure 5. 
 
Figure 5: Determination of Nodule-by-nodule Photobleaching. Progression from pre- and post-treatment and photobleaching 
difference map images to evaluation of the photobleaching pixel intensity profiles of selected nodules (circled in blue) for day 12 AsPC-1 
cultures receiving 1.5 hours and 4 hours uptake and 10 J/cm2 of light delivered (A) continuously or (B) asymmetrically fractionated. All 
scale bars are 350 μm. 





Figure 6: Depth of Cytotoxicity for Different Uptake 
and Light Delivery Treatments. (A) Inner and outer diame-
ters and (B) calculated depth of cytotoxicity, reported as (outer 
diameter – inner diameter)/2, for day 12 AsPC-1 nodules given 1.5 
hours and 4 hours of BPD uptake time and treated with 10 J/cm2 
delivered either continuously or asymmetrically fractionated. 
Error bars correspond to the standard deviation of the five indi-
vidual nodules selected per treatment group. 
 
 
To confirm this assertion, multiple nodules were 
selected from each uptake and light delivery group 
and the extent by which dead cells protruded into the 
nodules was assessed. The “depth of cytotoxicity” 
was chosen as a metric instead of “photobleaching 
depth” as the viability assessment images were much 
cleaner for analysis than the photobleaching maps. 
Though there is some dilation in the nodules during 
the 24 hour period between PDT treatment and eval-
uation, it is assumed that most of the change in size is 
due to dead cells detaching from the nodules and, as a 
result, is systematic across all nodules. Fluorescence 
images of the live and dead channels were first bina-
rized. The pixel intensities from the live fluorescence 
channel were subtracted element-wise from the dead 
channel, resulting in a difference mask consisting of 
the rings of white pixels (corresponding to dead re-
gions) with inner cores (live regions) of black pixels 
(not shown). Using ImageJ, multiple line scans were 
performed on each of five selected nodules per 
treatment group which presented similar outer diam-
eters along their minor axis. The outer and inner di-
ameters along the minor axes of the nodules were 
measured and the depth of cytotoxicity defined as the 
difference between the outer and inner diameters di-
vided by two.  
Figure 6 shows the results of this analysis for 
each group that received different BPD uptake time 
and irradiation schedules. A student’s t-test analysis 
gave that there is no significant difference in the outer 
diameters (Figure 6A) of each group of nodules se-
lected for line scan analysis. The inner diameter of the 
nodules collected from 4 hour uptake 10 J/cm2 
33s/99s group, however, was significantly different 
(p=0.003) than the 1.5 hour fractionated group. This 
resulted in a significant difference in the depth of cy-
totoxicity (p=0.040), as presented in Figure 6B. The 
average cytotoxic depth of the 4 hour uptake frac-
tionated group was also significantly thicker than in 
nodules that received both continuous irradiation 
treatments. There was a somewhat significant differ-
ence in the cytotoxic depth upon comparing contin-
uous to fractionated light delivery (p=0.018) in the 1.5 
hour uptake groups. Finally, there is a very significant 
change in cytotoxic depth when comparing continu-
ous irradiation to fractionation with 4 hours of pho-
tosensitizer uptake (p=0.003).  
Discussion and Conclusion 
The unique juxtaposition of high-content quan-
titative imaging of parameter-dependent spatiotem-
poral photosensitizer distribution and biological-
ly-relevant tumor models in this study yields several 
important insights that may be leveraged for en-
hanced PDT efficacy. The uptake curves of AsPC-1 
and PANC-1 cell lines in these 3D cultures are useful 
for the optimization of uptake-dependent PDT treat-
ment parameters, and are the first reported for this 
model. Our imaging-based technique shows that the 
localization of verteporfin in the nodules changes 
with increasing uptake time, quite dramatically 
within the first five hours. Given the large depth of 
focus in these images, it is probable that the nodule 
centers appear brighter than the cells in the periphery 
because more fluorescence is integrated from the 
thicker nodule cores at long uptake times. That is, 
while at certain time points, the cellular BPD concen-
tration is indeed higher in the outermost cells of the 
acinus than in the cells constituting the nodule core, it 
is highly unlikely that the variation ranges across or-




ders of magnitude. A future work might involve 
careful analysis of frozen sections obtained from a 
cyromicrotome thus allowing clearer visualization of 
cellular BPD concentrations in the acini cores at longer 
uptake times. Nevertheless, the increase in BPD con-
centration in the cells comprising the acini cores from 
1.5 to 4 hours uptake is an especially significant ob-
servation as most PDT treatments conducted with this 
3D model have utilized only ~1.5 hours of verteporfin 
uptake time, though in practice, pharmacokinetic 
considerations in vivo would determine the available 
window for uptake into the tumor [8]. A limitation of 
this model is the absence of any vasculature which, in 
vivo, would be a major source of PS delivery. The ab-
sence of blood flow in this model could also be par-
ticularly limiting when assessing various symmetric 
and asymmetric fractionation schemes as reoxygena-
tion times may be longer than diffusion-limited esti-
mates. That is, the vessels may need an extended pe-
riod of time to reload with oxyhemoglobin when 
subjected to heavy photodynamic consumption. 
However, extravasation from the vessels and tumor 
cell uptake is a diffusion phenomenon, so the above 
analysis and methodology remains a useful tool. 
The enhanced killing at low light doses with in-
creased uptake time for both cell lines suggests that 
fractionation may be more potent in the 3D model at 
long uptake times (i.e., ≥4 hours) and with fluences ≤5 
J/cm2 per light interval. For low light doses, an uptake 
time of 4 hours seems optimal as both cell lines show a 
marked plateau in BPD concentration, despite rising 
continuously out to 24 hours. Though the 24 hour data 
points for both uptake and cytotoxic response were 
important for this mechanistic study, the pharmaco-
kinetics of verteporfin do not permit 24 hours of up-
take in vivo [33]. While for AsPC-1 cells there was little 
dependence on uptake for treatment response at high 
light doses, the response of PANC-1 cultures to PDT 
treatment departs from AsPC-1 in that killing in-
creases going from 1.5 hours to 4 hours with all light 
doses. This is an expected result, however, as Figure 2 
shows there is far more photosensitizer in the 
PANC-1 nodules at 4 hours than at 1-2 hours of up-
take. 
Nodule-by-nodule photobleaching can be 
roughly correlated to cytotoxic response as shown in 
Figure 1. It is difficult to determine quantitatively, 
however, the correlation of the most photobleached 
regions of the acini to those regions containing the 
most dead cells. This is because the photobleaching 
maps presented here are derived from images col-
lected directly before and after PDT treatment, 
whereas quantitative viability assessments are de-
rived from images taken 24 hours post treatment. At 
this point, many of the dead cells have begun to mi-
grate away from the acini due to PDT disruption of 
the nodule structure [9]. The living nodule core has 
also had ample time to grow due to continuing mitotic 
division of the viable cells. Moreover, the loss of cell 
volume regulation in damaged cells can cause more 
variation in nodule size 24 hours post-treatment. As a 
result, it can be said qualitatively that the areas of 
greatest photobleaching are localized on the nodule 
crust and that this corresponds to regions of the 
greatest death, but the fluorescence intensity distri-
butions for the photobleaching map and dead chan-
nels will not line up perfectly with each other as the 
nodules’ surface area systematically enlarges during 
the 24 hour lag between treatment and evaluation. 
This effect can be seen in the line scan profile super-
position at the bottom of Figure 1. While this chal-
lenge remains to make the approach entirely quanti-
tative, for rapid screening of optimal conditions, it 
remains a useful qualitative tool as the extent of the 
inner diameter of the nodule in the dead channel (i.e., 
the point in the profile in which the live channel be-
gins to peak) matches fairly well to the corresponding 
inner diameter of the photobleaching scan (repre-
sented by the region of the nodule with the lowest 
degree of photobleaching).  
The 4 hour BPD uptake group with fractionated 
light delivery had a significantly thicker depth of cy-
totoxicity than continuous irradiation treatment with 
the same uptake (p=0.003) whereas this comparison at 
1.5 hours of uptake showed a much smaller (p=0.018), 
yet significant difference. This suggests that the depth 
of photobleaching is greater upon fractionation when 
sufficient BPD is available in the nodules. Fractiona-
tion likely does not show a significant benefit in mean 
cytotoxicity at 1.5 hours of uptake because of the 
scarcity of photosensitizer in the nodule cores. That is, 
reoxygenation of the nodule core would likely have 
little effect if there is not enough photosensitizer pre-
sent to utilize it. At 4 hours, as shown by fluorescence 
imaging, the cellular BPD concentration is higher in 
the nodule core than at 1.5 hours, allowing any reox-
ygenation intervals to be of use toward achieving su-
perior cytotoxic response. 
The small enhancement granted by asymmetric 
fractionation is expected when the spatial extent of 
nodules in this 3D model is considered. Despite the 
presence of hypoxic nodule cores in other 3D models 
of this type [28], these acini are not quite large enough 
to require extensive reoxygenation as with the vascu-
larized systems previously studied [13]. Theoretical 
oxygenation modeling studies with multicellular 
spheroids [34] and other in vivo geometries [24, 25] 
provide validity to this claim as optimal dark intervals 




for nodules of this size should be ≤5s. Despite these 
findings, it is interesting that cytotoxic response is 
enhanced with dark intervals as long as 99s; further 
exploration of fractionation in the 3D model using a 
refined version of our imaging-based technique may 
be performed in future work. In addition, though the 
enhancement in cytotoxicity between fractionated and 
continuous PDT treatment regimens is relatively 
modest in this 3D model, the result of unprecedented 
seconds-scale asymmetric fractionation merits further 
investigation in a model where reoxygenation is more 
important (i.e., murine mouse model). As the differ-
ences between continuous and symmetric fractionat-
ed light delivery were quite dramatic in previous in 
vivo studies [13, 25], it is possible that asymmetric 
fractionation could provide additional benefit.  
 In conclusion, the imaging-based approach pre-
sented here can be leveraged to visualize and quantify 
photosensitizer uptake characteristics, photobleach-
ing patterns, and cytotoxic response to make in-
formed decisions about in vitro PDT treatment pa-
rameters. Its utility may also be expanded to aid in 
optimization of in vivo PDT treatments of cancer. In 
addition, the result of asymmetric fractionation in the 
3D model suggests it may have additional benefit in 
vivo. Future work with fractionation in the 3D model 
and further refinement of our imaging technique may 
also lead to greater efficiency and enhancement of 
treatment parameters in both fractionated and con-
tinuous irradiation schemes. Finally, though not 
studied here, the effects of increased photosensitizer 
dose administered to the nodules could also be de-
termined using the imaging-based technique, leaving 
even more potential for further characterization and 
implementation of the method.  
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